medigraphic.com

2013, Number S1

<< Back Next >>

Rev Mex Anest 2013; 36 (S1)

Bleeding following deep hypothermia and circulatory arrest in children

Mossad EB

Language: English
References: 46
Page: 31-35
PDF size: 107.79 Kb.


Text Extraction

The burden of cardiac surgery on blood banks

The total blood supply, and blood bank resources in the Unites States remains a significant issue, despite improvements in methods of blood collection, processing and use of transfusion algorithms. In a review of US blood bank resources, the total annual US blood supply was over 13 million units of packed red blood cells (PRBC), and seven million units of platelets. Despite this large supply, daily reports from multiple sentinel sites monitoring the capacity to meet demands showed a median of the days’ supply for PRBC of 7.2 days, and only a 1-day supply of platelets.


REFERENCES

  1. Sullivan MT, Wallace EL. Blood collection and transfusion in the United States in 1999. Transfusion. 2005;45:141-148.

  2. Nightingale S, Wanamaker V, Silverman B, et al. Use of sentinel sites for daily monitoring of the US blood supply. Transfusion. 2003;43:364-372.

  3. Goodnough LT, Despotis GJ. Transfusion medicine: support of patients undergoing cardiac surgery. Am J Cardiovasc Drugs. 2001;1:337-351.

  4. Manno CS, Hedberg KW, Kim HC, et al. Comparison of the hemostatic effects of fresh whole blood, stored whole blood and components after open heart surgery in children. Blood. 1991;77:930-936.

  5. Mou SS, Giroir BP, Molitor-Kirsch EA, et al. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. N Engl J Med. 2004;351:1635-1644.

  6. Williams GD, Bratton SL, Ramamoorthy C. Factors associated with blood loss and blood product transfusions: a multivariate analysis on children after open-heart surgery. Anesth Analg. 1999;89:57-64.

  7. Williams GD, Bratton SL, Riley EC, et al. Coagulation tests during cardiopulmonary bypass correlate with blood loss in children undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 1999;13:398-404.

  8. DiNardo J. Physiology and techniques of extracorporeal circulation in the pediatric patient; in Pediatric Cardiac Anesthesia 4th edition, CB Lake, Editor. Lippincott Williams & Wilkins 2004:228-252.

  9. Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998-2005.

  10. Tempe DK, Virmani S. Coagulation abnormalities in patients with cyanotic congenital heart disease. J Cardiothorac Vasc Anesth. 2002;16:752-765.

  11. Kern FH, Morana NJ, Sears JJ, et al. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg. 1992;54:541-546.

  12. Horkay F, Martin P, Rajah M, et al. Response to heparinization in adults and children undergoing cardiac operations. Ann Thorac Surg. 1992;53:822-826.

  13. Boldt J, Knothe C, Zickmann B, et al. Comparison of two aprotinin dosage regimens. In: Pediatric patients having cardiac operations. Influence on platelet function and blood loss. J Thorac Cardiovasc Surg. 1993;105:705-711.

  14. Boldt J, Knothe C, Zickmann B, et al. Aprotinin in pediatric cardiac operations: platelet function, blood loss and use of homologous blood. Ann Thorac Surg. 1993;55:1460-1466.

  15. van Oeveren W, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg, 1987;44(6):640-645.

  16. Ekert H, et al. Hemostasis in cyanotic congenital heart disease. J Pediatr. 1970;76(2):221-230.

  17. Mossinger H, Dietrich W. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. Ann Thorac Surg. 1998;65(6 Suppl):S45-50; discussion S50-1, S74-6.

  18. Chan AK, et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost. 1997;77(2):270-277.

  19. Pang LM, et al. Increased circulating bradykinin during hypothermia and cardiopulmonary bypass in children. Circulation. 1979;60(7):1503-1507.

  20. Smith CR, Spanier TB. Aprotinin in deep hypothermic circulatory arrest. Ann Thorac Surg. 1999;68:278-286.

  21. Horrow J. Transfusion medicine and coagulation disorders. In: Cardiac Anesthesia, J.A. Kaplan, Editor. 1987, WB Saunders: Philadelphia. pp. 1111-1120.

  22. Nagaoka H, Katori M. Inhibition of kinin formation by a kallikrein inhibitor during extracorporeal circulation in open-heart surgery. Circulation. 1975;52(2):325-332.

  23. Blauhut B, et al. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991;101(6):958-967.

  24. Tabuchi N, et al. Aprotinin effect on platelet function and clotting during cardiopulmonary bypass. Eur J Cardiothorac Surg. 1994;8(2):87-90.

  25. Huang H, et al. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg. 1993;106(1):11-18.

  26. Shigeta O, et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation. 1997;96(2):569-574.

  27. Dietrich W. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? J Cardiovasc Pharmacol. 1996;27(Suppl 1):S50-57.

  28. Poullis M, et al. The antithrombotic effect of aprotinin: actions mediated via the protease activated receptor 1. J Thorac Cardiovasc Surg. 2000;120(2):370-378.

  29. John LC, Rees GM, Kovacs IB. Reduction of heparin binding to and inhibition of platelets by aprotinin. Ann Thorac Surg. 1993;55(5):1175-1179.

  30. Landis RC, et al. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg. 2001;72(6):2169-2175.

  31. Landis RC, Haskard DO, Taylor KM. New antiinflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg. 2001;72(5):S1808-1813.

  32. Elliott MAA. Aprotinin in pediatric cardiac surgery. Perfusion. 1990;5:73-76.

  33. Popov-Cenic, S.U., AE; Noe, G, Studies on the cause of bleeding during and after surgery with heart-lung-machine in children with cyanotic and acyanotic congenital cardiac defects and their prophylactic treatment, in Role of chemical mediators in the pathophysiology of acute illness injury. R. McConn, Editor. 1982, Raven: New York. p. 229-242.

  34. Penkoske PA, Entwistle LM, Marchak BE, et al. Aprotinin in children undergoing repair of congenital heart defects. Ann Thorac Surg. 1995;60:S529-S532.

  35. Royston D, et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2(8571):1289-1291.

  36. Mossinger H, Dietrich W, Braun SL, et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg. 2003;75:430-437.

  37. Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg. 1993;105:712-720.

  38. Tweddell JS, et al. Improved survival of patients undergoing palliation of hypoplastic left heart syndrome: lessons learned from 115 consecutive patients. Circulation. 2002;106(12 Suppl 1):I82-89.

  39. Mangano DT, Tudor IC, Dietzel C, et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-365.

  40. Pouard P. Review of efficacy parameters. Ann Thorac Surg. 1998;65(6 Suppl):S40-43; discussion S43-4, S74-6.

  41. Dietrich W, et al. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg. 1997;113(1):194-201.

  42. Chauhan S, Kumar BA, Rao BH, et al. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease. Ann Thorac Surg. 2000;70:1308-1312.

  43. Chauhan S, Das SN, Bisoi A, et al. Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. J Cardiothorac Vasc Anesth. 2004;18:141-143.

  44. Oliver WC, Santrach PJ, Danielson GK, et al. Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations. Ann Thorac Surg. 2000;70:1923-1930.

  45. Razon Y, Erez E, Vidne B, et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Pediatr Anesth. 2005;15:235-240.

  46. Dietrich W, Spannagl M. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg. 2002;94:1369-1377.




2020     |     www.medigraphic.com